Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection

by Elna eVan Der Ryst
Published 2015-06-01

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc

by ME Lewis, B Jubb, P Simpson, A Lopatukhin, D Kireev, M Bobkova, C Craig, E van der Ryst, M Westby, SL Butler
Published 2021-06-01

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optim...

by ME Lewis, P Simpson, J Mori, B Jubb, J Sullivan, L McFadyen, E van der Ryst, C Craig, DL Robertson, M Westby
Published 2021-07-01